Physician
Plastic Surgery
Dr. David R. Bowen, MD
|
|
Give Review
David Bowen practices Plastic Surgery. He attended Baylor College of Medicine. David Bowen is a published physician. He has 70 papers published. The most current publication "Poor response rate to a continuous schedule of Amifostine therapy for ''low/intermediate risk'' myelodysplastic patients." David Bowen accepts Medicare.
Publications
- Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
- Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome.
- Time-dependent prognostic scoring system for myelodysplastic syndromes has significant limitations that may influence its reproducibility and practical application.
- Etiology of acute myeloid leukemia in the elderly.
- RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years.
- Treatment strategies and issues in low/intermediate-1-risk myelodysplastic syndrome (MDS) patients.
- CYP1A1*2B (Val) allele is overrepresented in a subgroup of acute myeloid leukemia patients with poor-risk karyotype associated with NRAS mutation, but not associated w...
- Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemog...
- Serum erythropoietin and erythropoiesis in patients with myelodysplastic syndromes.
- Cyclical haemopoiesis in association with familial refractory anaemia: cycling of progenitors and serum growth factor concentrations.
- Secondary myelodysplasia of donor cell origin following nonmyeloablative sibling allogeneic stem cell transplantation.
- Delayed haemolytic transfusion reaction due to simultaneous appearance of anti-Fya and Anti-Fy5.
- Serum erythropoietin following cytostatic therapy.
- Secondary erythrocytosis and sarcoidosis.
- The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts.
- In vitro growth of myeloid and erythroid progenitor cells from myelodysplastic patients in response to recombinant human granulocyte-macrophage colony-stimulating factor.
- Estimation of effective and total erythropoiesis in myelodysplasia using serum transferrin receptor and erythropoietin concentrations, with automated reticulocyte para...
- Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes.
- Mitochondrial oxygen consumption and ineffective haematopoiesis in patients with myelodysplastic syndromes.
- Defining the pathogenic role of telomerase mutations in myelodysplastic syndrome and acute myeloid leukemia.
- Growth response to cytokines of circulating myeloid progenitors from myelodysplastic patients at diagnosis and more than 600 days after diagnosis.
- Pathogenesis, etiology and epidemiology of myelodysplastic syndromes.
- Cutaneous vasculitis in patients with myelodysplasia.
- The role of the Sysmex SE9000 immature myeloid index and Sysmex R2000 reticulocyte parameters in optimizing the timing of peripheral blood stem cell harvesting in pati...
- Micromegakaryocytes in CSF.
- Transfusion-associated graft vs. host disease in a patient with high-grade B-cell lymphoma. Should cellular products for patients with non-Hodgkin''s lymphoma be irrad...
- Low-dose melphalan in elderly acute myeloid leukaemia: complete remissions but resistant relapse with therapy-related karyotypes.
- In vitro development of haemopoietic progenitors in myelodysplastic syndromes (MDS)
- Oxidative DNA damage in CD34+ myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor-alpha concentration.
- No increase in age-specific incidence of myelodysplastic syndromes.
- Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia.
- Colony-cluster ratio and cluster number in cultures of circulating myeloid progenitors as indicators of high-risk myelodysplasia.
- Cytogenetic abnormalities in the myelodysplastic syndromes and occupational or environmental exposure.
- Circulating erythropoietin in patients with myelodysplastic syndromes.
- Clonal karyotype abnormalities and clinical progress in the myelodysplastic syndrome.
- Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion.
- Oxidative stress and the myelodysplastic syndromes.
- Two new polymorphisms but no mutations of the KIT gene in patients with myelodysplasia at positions corresponding to human FMS and murine W locus mutational hot spots.
- Refractory anaemia with preleukaemic polyclonal haemopoiesis and the emergence of monoclonal erythropoiesis on disease progression.
- Evolving trends in the treatment of low-risk myelodysplastic syndromes: immunomodulation and beyond--9th European Hematology Association Congress Geneva, Switzerland, ...
- Identification of disease- and therapy-associated proteome changes in the sera of patients with myelodysplastic syndromes and del(5q).
- Glutathione S-transferase enzyme expression in hematopoietic cell lines implies a differential protective role for T1 and A1 isoenzymes in erythroid and for M1 in lymp...
- Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.
- Thalidomide therapy for low-risk Myelodysplasia.
- JAK2 V617F Mutation is uncommon in chronic myelomonocytic leukaemia.
- Predicting erythroid response to recombinant erythropoietin plus granulocyte colony-stimulating factor therapy following a single subcutaneous bolus in patients with m...
- Antioxidant enzyme expression in myelodysplastic and acute myeloid leukemia bone marrow: further evidence of a pathogenetic role for oxidative stress?
- Functional disturbance of marrow stromal microenvironment in the myelodysplastic syndromes.
- Assessment of stromal function, and its potential contribution to deregulation of hematopoiesis in the myelodysplastic syndromes.
- Mutant RAS selectively promotes sensitivity of myeloid leukemia cells to apoptosis by a protein kinase C-dependent process.
- Population-based demographic study of karyotypes in 1709 patients with adult acute myeloid leukemia.
- Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes.
- Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia.
- Mutations in PTPN11 are uncommon in adult myelodysplastic syndromes and acute myeloid leukaemia.
- Best supportive care for the anaemia of myelodysplasia: inclusion of recombinant erythropoietin therapy?
- Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia.
- Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome.
- A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.
- The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and re...
- Poor response rate to a continuous schedule of Amifostine therapy for ''low/intermediate risk'' myelodysplastic patients.
- Allele and haplotype frequency at human leucocyte antigen class I/II and immunomodulatory cytokine loci in patients with myelodysplasia and acute myeloid leukaemia: in...
- Second hit mutations in the RTK/RAS signaling pathway in acute myeloid leukemia with inv(16).
- A pilot study of antithymocyte globulin (ATG) in the treatment of patients with ''low-risk'' myelodysplasia.
- Latency of onset of de novo myelodysplastic syndromes.
- NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q).
- Chronic myelomonocytic leukemia: lost in classification?
- Analysis of the CD33-related siglec family reveals that Siglec-9 is an endocytic receptor expressed on subsets of acute myeloid leukemia cells and absent from normal h...
- Epigenetic mechanisms regulating normal and malignant haematopoiesis: new therapeutic targets for clinical medicine.
- Introduction to an occasional series.
Schools
Loma Linda University
White Meml Med Center
East Va Grad School Med
University Of Florida College Of Med
Doctors Specialties
- Diagnostic Radiology
- Plastic Surgery
Accepted Insurances
Education
-
University of Southern California - LAC+USC Medical Center -
Baylor College of Medicine
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1255419149 |
| Last Name Of The Provider | BOWEN |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
Dr. Joseph R. Burlin, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James Kim, MD |
|
|
Dr. Francis Isidoro, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. William A. Federal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Oscar O. Isidoro, MD |
|
|
Dr. Randall J. Enstrom, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John S. Silverton, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles A. Stillman, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brad R. Nanigian, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Nathan A. Kludt, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hugh L. Vu, MD |
|
|
Dr. Clifton L. Choo, MD |